Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-09-12 4:38 pm Purchase | 2025-09-10 | 13G | Talphera, Inc. TLPH | Rock Springs Capital Management LP | 3,589,186 7.880% | 3,589,186 (New Position) | Filing History |
| 2025-08-13 4:31 pm Sale | 2025-06-30 | 13G | Inozyme Pharma, Inc. INZY | Rock Springs Capital Management LP | 0 0.000% | -3,681,174 (Position Closed) | Filing History |
| 2025-08-13 4:31 pm Sale | 2025-07-03 | 13G | Spruce Biosciences, Inc. SPRB | Rock Springs Capital Management LP | 0 0.000% | -2,609,125 (Position Closed) | Filing History |
| 2025-05-15 10:48 am Sale | 2025-03-31 | 13G | Xilio Therapeutics, Inc. XLO | Rock Springs Capital Management LP | 0 0.000% | -3,003,259 (Position Closed) | Filing History |
| 2025-05-15 10:47 am Sale | 2025-03-31 | 13G | Travere Therapeutics, Inc. TVTX | Rock Springs Capital Management LP | 2,921,196 3.300% | -2,052,453 (-41.27%) | Filing History |
| 2025-05-15 10:46 am Sale | 2025-03-31 | 13G | Mereo BioPharma Group plc MREO | Rock Springs Capital Management LP | 33,421,235 4.200% | -14,249,615 (-29.89%) | Filing History |
| 2025-05-15 10:45 am Sale | 2025-03-31 | 13G | Aclaris Therapeutics, Inc. ACRS | Rock Springs Capital Management LP | 5,046,309 4.700% | -1,715,552 (-25.37%) | Filing History |
| 2025-02-14 09:10 am Purchase | 2024-12-31 | 13G | Travere Therapeutics, Inc. TVTX | Rock Springs Capital Management LP | 4,973,649 5.720% | 561,666 (+12.73%) | Filing History |
| 2024-11-22 4:00 pm Purchase | 2024-11-18 | 13G | Aclaris Therapeutics, Inc. ACRS | Rock Springs Capital Management LP | 6,761,861 6.320% | 3,763,366 (+125.51%) | Filing History |
| 2024-11-12 4:50 pm Unchanged | 2024-09-30 | 13G | Xilio Therapeutics, Inc. XLO | Rock Springs Capital Management LP | 3,003,259 6.830% | 0 (Unchanged) | Filing History |
| 2024-11-12 4:49 pm Purchase | 2024-09-30 | 13G | Mereo BioPharma Group plc MREO | Rock Springs Capital Management LP | 47,670,850 6.200% | 7,751,595 (+19.42%) | Filing History |
| 2024-11-12 4:47 pm Sale | 2024-09-30 | 13G | Immunocore Holdings plc IMCR | Rock Springs Capital Management LP | 0 0.000% | -2,661,507 (Position Closed) | Filing History |
| 2024-05-01 4:11 pm Purchase | 2024-04-25 | 13G | Travere Therapeutics, Inc. TVTX | Rock Springs Capital Management LP | 4,411,983 5.790% | 4,411,983 (New Position) | Filing History |
| 2024-04-05 2:51 pm Purchase | 2024-03-27 | 13G | Xilio Therapeutics, Inc. XLO | Rock Springs Capital Management LP | 3,003,259 8.710% | 3,003,259 (New Position) | Filing History |
| 2024-02-14 2:12 pm Purchase | 2023-12-31 | 13G | Compass Therapeutics, Inc. CMPX | Rock Springs Capital Management LP | 1,440,759 5.230% | 1,440,759 (New Position) | Filing History |
| 2024-02-14 2:12 pm Sale | 2023-12-31 | 13G | Tempest Therapeutics, Inc. TPST | Rock Springs Capital Management LP | 0 0.000% | -63,358 (Position Closed) | Filing History |
| 2024-02-14 2:11 pm Purchase | 2023-12-31 | 13G | Spruce Biosciences, Inc. SPRB | Rock Springs Capital Management LP | 34,788 6.410% | 13,152 (+60.79%) | Filing History |
| 2024-02-14 2:11 pm Unchanged | 2023-12-31 | 13G | Mereo BioPharma Group plc MREO | Rock Springs Capital Management LP | 39,919,255 5.690% | 0 (Unchanged) | Filing History |
| 2024-02-14 2:10 pm Purchase | 2023-07-03 | 13G | Mereo BioPharma Group plc MREO | Rock Springs Capital Management LP | 39,919,255 6.380% | 8,694,770 (+27.85%) | Filing History |
| 2024-02-14 2:10 pm Purchase | 2023-12-31 | 13G | Inozyme Pharma, Inc. INZY | Rock Springs Capital Management LP | 3,681,174 5.960% | 595,147 (+19.29%) | Filing History |